A secondary analysis of the EMPULSE trial provides more context to the quality-of-life benefits of the early initiation of empagliflozin in patients hospitalized with acute decompensated heart failure.
Study shows patients with acute heart failure assigned the SGLT2 inhibitor empagliflozin saw a greater improvement in HF symptoms, physical limitations and quality of life measures vs. placebo.